disorder that affects about 0.1% of the population. It causes daily bouts of intense pain for a period of weeks to months at a time.
The trial, of 106 patients, tested a new injection drug called galcanezumab, meant to prevent cluster headaches. In the three weeks after one injection, patients suffered about nine fewer headaches per week — versus five fewer among patients given a placebo injection.
The researchers, led by Dr. Peter Goadsby of King’s College London in England, said larger, longer studies are needed to see if the benefit holds up.
More information
For more facts and resources for migraines, visit the American Migraine Foundation.
